IPO
IPO filing, visualized

Electra Therapeutics, Inc.

ETRA · Nasdaq424B4 · Sep 18, 2026Priced Sep 17, 2026

Priced Sep 17, 2026 · range was $14–$16 · latest SEC filing Nov 16, 2026.

Pinch-zoom for details.

The offering

Final price
$15.00
per share, from the final prospectus
Shares offered
23.3M
+3.50M over-allotment option
Raise at the final price
$350M
23,333,334 × $15, before fees

What the company does

Not yet summarized; the SEC classifies it as: Biological Products, (No Diagnostic Substances). See the filing for its business.

Operating result

Fiscal year

1st half

Net result

Fiscal year

1st half

Things to weigh

  • Loss-making: net loss of $48.9M in H1 2026.

The numbers

$FY2024FY2025YoYH1 2025H1 2026Change
Operating result(26.3M)(61.9M)−135%(25.4M)(50.2M)−98.0%
Net result(24.8M)(62.0M)−150%(25.4M)(48.9M)−92.9%
$FY2024FY2025YoY
Operating result(26.3M)(61.9M)−135%
Net result(24.8M)(62.0M)−150%
$H1 2025H1 2026Change
Operating result(25.4M)(50.2M)−98.0%
Net result(25.4M)(48.9M)−92.9%

Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.

Risks

The filing doesn't set out its risks in a list we could read.

Strategy

The filing doesn't set out its strategy in a list we could read.

Source: Electra Therapeutics, Inc.'s Form 424B4, filed with the SEC on Sep 18, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.